CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Memorial Sloan Kettering Cancer Center
Amgen
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
Lyell Immunopharma, Inc.
BeOne Medicines
Yale University
Genmab
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
St. Jude Children's Research Hospital
Beijing Biotech
Gilead Sciences
Memorial Sloan Kettering Cancer Center
Otsuka Pharmaceutical Co., Ltd.
Autolus Limited
Hoosier Cancer Research Network
Affiliated Hospital to Academy of Military Medical Sciences
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
SecuraBio
University of Utah
The First Affiliated Hospital of Soochow University
Medical College of Wisconsin
AstraZeneca
Novartis
Takeda
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Fudan University
Amgen
Health Institutes of Turkey
AbbVie
Pfizer
AstraZeneca
Treeline Biosciences, Inc.
C4 Therapeutics, Inc.
Canadian Cancer Trials Group
Sumitomo Pharma America, Inc.
Novartis
Chinese PLA General Hospital
MSD R&D (China) Co., Ltd.
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sellas Life Sciences Group
Memorial Sloan Kettering Cancer Center